ArticleCommunications biology2021
3D tumor spheroid microarray for high-throughput, high-content natural killer cell-mediated cytotoxicity.
Article in Communications biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 70 citations in OpenAlex.
- NOHA as a key biomarker to link NOS2 activity to immune checkpoint and cytokine signaling in ER-negative breast cancer.Biochemistry and biophysics reports · 2026Article
- Resident CD49aScience advances · 2026Article
- Cytokine preactivation and ADCC: a potent strategy for enhancing human NK cell effector functions against 3D tumor models.Frontiers in immunology · 2026Article
- Three-Dimensional Tumor Spheroids of Pancreatic and Colorectal Cancer Cell Lines for High-Throughput Screening of Drug Candidates.ACS omega · 2025Article
- Properties of 3-Dimensional Cell Cultivation Matrices and Scaffolds in Magnetic Resonance Imaging at 3 Tesla.Journal of functional biomaterials · 2025Article
- A 3D tumor spheroid model with robust T cell infiltration for evaluating immune cell engagers.iScience · 2025Article
- Geometrical constraints dictate assembly and phenotype of human iPSC-derived motoneuronal spheroids.Stem cell research & therapy · 2025Article
- Exploring the Complexity of Cutaneous Squamous CellCarcinoma Microenvironment: Focus on Immune Cell Roles by Novel 3D In Vitro Models.Life (Basel, Switzerland) · 2025Review
- 3D-Organoid-SwinNet: High-Content Profiling of 3D Organoids.IEEE journal of biomedical and health informatics · 2025Article
- Diffusion Smart-seq3 of breast cancer spheroids to explore spatial tumor biology and test evolutionary principles of tumor heterogeneity.Scientific reports · 2025Article
- Pharmacological Vitamin C-induced high HJournal of translational medicine · 2025Article
- Advancing cancer research through 3D cell culture models.EXCLI journal · 2025Review
- ADCC: the rock band led by therapeutic antibodies, tumor and immune cells.Frontiers in immunology · 2025Review
- Article
- A Novel Tetravalent Bispecific Immune Cell Engager Activates Natural Killer Cells to Kill Cancer Cells without Mediating Fratricide.Antibodies (Basel, Switzerland) · 2024Article
- Comprehensive assessment of TECENTRIQ® and OPDIVO®: analyzing immunotherapy indications withdrawn in triple-negative breast cancer and hepatocellular carcinoma.Cancer metastasis reviews · 2024Review
- Unveiling the functional roles of patient-derived tumour organoids in assessing the tumour microenvironment and immunotherapy.Clinical and translational medicine · 2024Review
- Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using malignant pleural effusion.NPJ precision oncology · 2024Article
- Mineralized collagen scaffolds for regenerative engineering applications.Current opinion in biotechnology · 2024Review
- Empowering pancreatic tumor homing with augmented anti-tumor potency of CXCR2-tethered CAR-NK cells.Molecular therapy. Oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy has emerged as a promising approach to treating several forms of cancer. Use of immune cells, such as natural killer (NK) cells, along with small molecule drugs and antibodies through antibody dependent cell-mediated cytotoxicity (ADCC) has been investigated as a potential combination therapy for some difficult to treat solid tumors. Nevertheless, there remains a need to develop tools that support co-culture of target cancer cells and effector immune cells in a contextually relevant three-dimensional (3D) environment to provide a rapid means to screen for and optimize ADCC-drug combinations. To that end, here we have developed a high throughput 330 micropillar-microwell sandwich platform that enables 3D co-culture of NK92-CD16 cells with pancreatic (MiaPaCa-2) and breast cancer cell lines (MCF-7 and MDA-MB-231). The platform successfully mimicked hypoxic conditions found in a tumor microenvironment and was used to demonstrate NK-cell mediated cell cytotoxicity in combination with two monoclonal antibodies; Trastuzumab and Atezolizumab. The platform was also used to show dose response behavior of target cancer cells with reduced EC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.